Replies to post #1098 on Bristol Myers Squibb (BMY)

[DewDiligence]

BMY 2Q22 CC slides:

https://s21.q4cdn.com/104148044/files/doc_presentations/2022/BMY-2022-Q2-Results-Investor-Presentation.pdf

[DewDiligence]

BMY 3Q22 results—2022 non-GAAP guidance unchanged:

https://www.businesswire.com/news/home/20221026005143/en

Non-GAAP EPS guidance remains $7.44-7.74.

This PR wasn’t supposed to come out until Wednesday morning. (Somebody must have goofed.)